<DOC>
	<DOCNO>NCT02292537</DOCNO>
	<brief_summary>The primary objective study examine clinical efficacy nusinersen ( ISIS 396443 ) administer intrathecally participant later-onset Spinal Muscular Atrophy ( SMA ) . The secondary objective examine safety tolerability nusinersen administer intrathecally participant later-onset SMA .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Nusinersen ( ISIS 396443 ) Participants With Later-onset Spinal Muscular Atrophy ( SMA )</brief_title>
	<detailed_description>This study conduct protocol register Ionis Pharmaceuticals , Inc . In August 2016 , sponsorship trial transfer Biogen .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Parent guardian sign informed consent , indicate per participant 's age institutional guideline , participant sign inform assent Be medically diagnose Spinal Muscular Atrophy ( SMA ) Have onset clinical sign symptom consistent SMA great 6 month age Be able sit independently , never ability walk independently Have Motor Function Score ( Hammersmith Functional Motor Scale Expanded ) great equal 10 less equal 54 Screening Be able complete study procedure , measurement visit parent guardian subject adequately supportive psychosocial circumstance , opinion Investigator Have estimate life expectancy great 2 year Screening , opinion Investigator Meet ageappropriate institutional criterion use anesthesia sedation , use plan study procedure For subject reach reproductive maturity , satisfy study contraceptive requirement Key Respiratory insufficiency , define medical necessity invasive noninvasive ventilation great 6 hour 24 hour period , Screening Medical necessity gastric feed tube , majority feed give route , assess Site Investigator Severe contractures severe scoliosis evident Xray examination Screening Hospitalization surgery ( i.e. , scoliosis surgery , surgery ) , pulmonary event , nutritional support within 2 month Screening plan duration study Presence untreated inadequately treat active infection require systemic antiviral antimicrobial therapy time screen period History brain spinal cord disease , include tumor , abnormality MRI CT would interfere LP procedure CSF circulation Presence implant shunt drainage CSF implant CNS catheter History bacterial meningitis Dosing IONISSMN Rx previous clinical study Prior injury ( e.g. , upper low limb fracture ) surgical procedure impact subject 's ability perform outcome measure test require protocol subject fully recover achieve stable baseline Clinically significant abnormality hematology clinical chemistry parameter ECG , assess Site Investigator , Screening visit would render subject unsuitable inclusion Treatment another investigational drug ( e.g. , oral albuterol salbutamol , riluzole , carnitine , creatine , sodium phenylbutyrate , et.c ) , biological agent , device within 1month Screening 5 halflives study agent , whichever longer . Treatment valproate hydroxyurea within 3months Screening . Any history gene therapy , antisense oligonucleotide therapy , cell transplantation . Ongoing medical condition accord Site Investigator would interfere conduct assessment study . Examples medical disability ( e.g. , waste cachexia , severe anemia , etc . ) would interfere assessment safety would compromise ability subject undergo study procedure . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>SMN</keyword>
	<keyword>SMNRx</keyword>
	<keyword>ISIS-SMNRx</keyword>
	<keyword>ISIS-SMN Rx</keyword>
	<keyword>ISIS 396443</keyword>
	<keyword>CHERISH</keyword>
	<keyword>IONIS-SMNRx</keyword>
	<keyword>IONIS-SMN Rx</keyword>
</DOC>